What Is Cagrilintide?
Cagrilintide is an investigational long-acting amylin analogue being studied for weight management and type 2 diabetes. Amylin is a hormone released by the pancreas after eating. It helps regulate appetite, slows the movement of food from the stomach, and supports blood-glucose control.
Unlike approved medicines such as semaglutide or tirzepatide, cagrilintide is not currently approved as a standalone treatment in many regions. It has mainly been evaluated in clinical trials, including studies of cagrilintide alone and in combination with semaglutide. The combination is commonly known as CagriSema.
Because cagrilintide is still under investigation, the available safety information comes from clinical trials rather than years of routine prescribing. The side effects reported so far are generally similar to those associated with other appetite-regulating injectable medicines, especially gastrointestinal symptoms. However, the frequency and severity can vary according to dose, treatment combination, and the health of the person taking it.
The Most Common Cagrilintide Side Effects
In clinical studies, the most frequently reported adverse effects involved the digestive system. These effects were usually mild to moderate and tended to occur during dose escalation or shortly after treatment began.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite
- Abdominal discomfort or pain
- Indigestion or dyspepsia
- Feeling unusually full
Nausea is one of the most consistently reported cagrilintide side effects. This is not unexpected because amylin-based medicines influence appetite and gastric emptying. Some participants in trials also reported vomiting, particularly at higher doses or while increasing the dose.
Digestive symptoms may affect food and fluid intake. For many people, the symptoms improve as the body adjusts to treatment. Even so, persistent nausea, repeated vomiting, or severe diarrhea can lead to dehydration and may require medical advice.
Nausea and Vomiting
Nausea may range from a mild unsettled feeling to symptoms that interfere with normal meals and daily activities. Vomiting was reported less often than nausea, but it remains an important potential side effect, especially during dose escalation.
Eating smaller meals, avoiding very fatty foods, and drinking fluids slowly may help some people manage mild nausea. People should not change the dose or stop treatment without speaking with their healthcare professional. Severe or ongoing vomiting requires prompt medical attention, particularly if there are signs of dehydration such as dizziness, fainting, confusion, a dry mouth, or very dark urine.
Constipation and Diarrhea
Changes in bowel habits have also appeared in cagrilintide studies. Constipation may occur because the medicine can reduce food intake and influence gastrointestinal movement. Diarrhea can have the opposite effect and may be more troublesome when combined with other weight-loss medicines.
A healthcare professional may recommend dietary changes, increased fluids, or an appropriate treatment for constipation or diarrhea. Sudden severe abdominal pain, a swollen abdomen, inability to pass stool or gas, or blood in the stool should be assessed urgently.
Side Effects Reported With Cagrilintide and Semaglutide
Much of the recent interest in cagrilintide comes from combination treatment. CagriSema combines cagrilintide with semaglutide, a glucagon-like peptide-1 receptor agonist. Clinical trials have reported substantial weight loss with this combination, but the treatment may also produce more gastrointestinal symptoms than either medicine alone.
Reported effects in combination studies have included:
- Nausea, particularly during dose escalation
- Vomiting
- Constipation
- Diarrhea
- Decreased appetite
- Abdominal pain or discomfort
- Injection-site reactions
- Fatigue or headache in some participants
In trials, adverse effects were often managed by gradually increasing the dose. Some participants required a slower dose escalation, temporary interruption, or discontinuation. It is important to interpret trial results carefully because people in research studies receive regular monitoring and may differ from individuals using a medicine in routine practice.
Less Common but Serious Risks
Most cagrilintide side effects reported in trials have been gastrointestinal and non-serious. However, medicines in this class may involve risks that require medical attention. Since cagrilintide remains investigational, its complete long-term safety profile is not yet known.
Pancreatitis
Severe and persistent abdominal pain, especially pain that spreads to the back and is accompanied by vomiting, may indicate pancreatitis. Anyone experiencing these symptoms should seek urgent medical assessment. People with a history of pancreatitis should discuss the potential risks and alternatives with a qualified clinician before using an investigational appetite-regulating medicine.
Gallbladder Problems
Rapid weight loss and weight-management medicines may be associated with gallstones or inflammation of the gallbladder. Warning signs can include strong pain in the upper right or upper middle abdomen, fever, nausea, vomiting, or yellowing of the skin or eyes.
Not every case of abdominal discomfort represents gallbladder disease, but severe or persistent symptoms should not be ignored.
Dehydration and Kidney Problems
Vomiting and diarrhea can cause significant fluid loss. Dehydration may place extra stress on the kidneys, particularly in people who already have kidney disease or take medicines that affect fluid balance.
People using cagrilintide in a clinical trial should report ongoing gastrointestinal symptoms to the study team. Laboratory monitoring may be needed if symptoms are severe or prolonged.
Allergic Reactions
As with any injectable medicine, an allergic reaction is possible. Urgent symptoms include swelling of the face, lips, tongue, or throat; difficulty breathing; widespread hives; severe dizziness; or fainting. These symptoms require emergency care.
How Common Are Cagrilintide Side Effects?
The exact rates depend on the specific clinical trial, dose, treatment duration, and whether cagrilintide was used alone or with semaglutide. In general, gastrointestinal adverse effects were reported more often at higher doses and during the early stages of treatment.
Trial findings also show that side effects do not affect every participant in the same way. Some people have minimal symptoms, while others may find nausea or bowel changes difficult to tolerate. The presence of a side effect does not necessarily mean the medicine is unsafe for everyone, but it can affect whether treatment is suitable for a particular person.
Researchers also record serious medical events that occur during a trial, even when they are not proven to be caused by the study medicine. This distinction matters. A reported event is not automatically a confirmed drug reaction. Regulators and researchers assess timing, frequency, medical history, and comparisons with placebo or other treatments before drawing conclusions.
Who May Need Extra Caution?
Cagrilintide may not be appropriate for everyone. Before entering a trial or considering any future approved treatment, people should discuss their medical history and current medicines with a healthcare professional.
Extra caution may be appropriate for people with:
- A history of pancreatitis or significant gallbladder disease
- Severe gastrointestinal disorders or delayed stomach emptying
- Kidney disease or a high risk of dehydration
- Serious liver disease
- A history of severe allergic reactions to injectable medicines
- Pregnancy, planned pregnancy, or breastfeeding
- A personal or family history relevant to medicines in the same therapeutic area
People with diabetes may also need closer monitoring. Reduced food intake, vomiting, or changes in other diabetes medicines can affect blood-glucose levels. Cagrilintide should not be combined with prescription or non-prescription weight-loss products unless a healthcare professional specifically advises it.
When to Contact a Doctor
Mild nausea or temporary changes in bowel habits may occur during treatment, but certain symptoms require prompt medical advice. Contact a healthcare professional if side effects are severe, persistent, or interfere with eating and drinking.
Seek urgent help for:
- Severe or worsening abdominal pain
- Repeated vomiting or inability to keep fluids down
- Signs of dehydration, fainting, or confusion
- Yellow skin or eyes, pale stools, or dark urine
- Swelling of the face or throat, breathing difficulties, or widespread hives
- Severe weakness or symptoms of very low blood sugar when other glucose-lowering medicines are being used
What the Trial Data Means for Patients
The current evidence suggests that the main cagrilintide side effects are gastrointestinal, particularly nausea, vomiting, constipation, diarrhea, and reduced appetite. These effects are often linked to dose escalation and may improve over time, but they can still lead some participants to reduce their dose or stop treatment.
At the same time, trial data cannot answer every long-term safety question. Cagrilintide is still being studied, and its safety profile may become clearer as larger and longer clinical trials are completed. Results from combination treatment with semaglutide should not automatically be applied to cagrilintide alone.
Anyone considering cagrilintide should rely on information from clinical-trial investigators, regulatory agencies, and qualified healthcare professionals rather than unapproved products sold online. Until the medicine receives regulatory approval for a specific use, its quality, dose, and safety outside a properly supervised research setting may be uncertain.
